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Abstract
Pancreatic islet transplantation has been considered for many years a promising therapy for
beta-cell replacement in patients with type-1 diabetes despite that long-term clinical results
are not as satisfactory. This fact points to the necessity of designing strategies to improve
and accelerate islets engraftment, paying special attention to events assuring their revascu-
larization. Fibroblasts constitute a cell population that collaborates on tissue homeostasis,
keeping the equilibrium between production and degradation of structural components as
well as maintaining the required amount of survival factors. Our group has developed a
model for subcutaneous islet transplantation using a plasma-based scaffold containing
fibroblasts as accessory cells that allowed achieving glycemic control in diabetic mice.
Transplanted tissue engraftment is critical during the first days after transplantation, thus we
have gone in depth into the graft-supporting role of fibroblasts during the first ten days after
islet transplantation. All mice transplanted with islets embedded in the plasma-based scaf-
fold reversed hyperglycemia, although long-term glycemic control was maintained only in
the group transplanted with the fibroblasts-containing scaffold. By gene expression analysis
and histology examination during the first days we could conclude that these differences
might be explained by overexpression of genes involved in vessel development as well as in
β-cell regeneration that were detected when fibroblasts were present in the graft. Further-
more, fibroblasts presence correlated with a faster graft re-vascularization, a higher insulin-
positive area and a lower cell death. Therefore, this work underlines the importance of fibro-
blasts as accessory cells in islet transplantation, and suggests its possible use in other graft-
supporting strategies.
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Introduction
Pancreatic islet transplantation has been considered along the last two decades as a promising
therapy for beta-cell replacement in patients with type-1 diabetes. This strategy reduce the
risks associated to whole-pancreas transplantation and is specially indicated to those patients
with unstable glycemic control, hypoglycemia unawareness and/or resistance to intensive
insulin-based therapies [1]. Nevertheless, although most of islet recipients remained protected
from recurrent hypoglycemia, less than 50% maintained insulin independence five years after
islet transplantation [2, 3]. Thus, this long-term loss-of-function evidence the necessity of
improving some aspects of islet transplantation, especially those addressing obstacles like
engraftment and transplantation site [4].
In addition to a supporting matrix or scaffold, an optimal engraftment site requires access
to adequate oxygen and nutrient supplies either from endogenous vasculature or from induced
or intrinsic neovascularization [5]. During the first days after transplantation, when the islet
graft is avascular, up to 60% of the islet mass can be lost [6]. Thus, graft revascularization plays
a critical role in islet viability and function [7], as well as in restoration of the islet-extracellular
matrix interactions [8]. Several sites have been proposed as alternative to intrahepatic islet
transplantation. Among them, subcutaneous space stands out because of its accessibility and
spaciousness, although its poor vascularization constitutes its main limitation [9]. Taking this
in mind, improvement of angiogenesis becomes crucial for successful subcutaneous islet trans-
plantation. Several attempts have been conducted, mainly focused on the use of different bio-
materials as scaffolds, either alone or in combination with pro-angiogenic factors and, more
recently, in combination with accessory cells with graft-supporting properties.
Fibroblasts are a heterogeneous mesenchymal-derived cell population with different char-
acteristics depending on their tissue of origin [10]. These cells collaborate on extracellular
matrix and connective tissue formation producing several molecules as metalloproteinases,
collagen, fibronectins and proteoglicans [11], which provide support for organ structures,
including blood vessels. Moreover, fibroblasts secrete per se or under hypoxic conditions sev-
eral factors (VEGF, FGF, PDGF, HIF-1α), of which some are potent angiogenic factors [12].
Our group has developed a model for subcutaneous islet transplantation using a plasma-
based scaffold containing fibroblasts as graft-supporting accessory cells that allowed long-term
glycemic control in diabetic immune-deficient mice [13]. Moreover, combination of fibro-
blasts with immunomodulatory mesenchymal stem cells (MSCs) was also able to temporarily
control blood glucose levels in immune-competent mice [14].
In the present work we have gone in depth using gene expression analysis and immunohis-
tochemistry techniques into the graft-supporting role of fibroblasts in this subcutaneous islet
transplantation model. Taking in mind that revascularization begins 2–4 days after transplan-
tation and is mostly complete by 10–14 days [15], we focus our study on this period, when a




Twelve-week-old male Wistar rats (Animal Facilities of University of Oviedo, Oviedo, Spain)
were used as pancreatic islet donors. Six-week-old male Swiss nu/nu mice (Harlan Iberica,
Barcelona, Spain) were used as immunodeficient recipients. Mice were rendered diabetic by a
single intraperitoneal injection of 225 mg/kg body weight of streptozotocin (Sigma-Aldrich,
Madrid, Spain). Diabetes was defined as non-fasting blood glucose (NFBG) levels higher than
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450 mg/dL determined in two consecutive days. This study was carried out in strict accordance
with the guidelines of the European Union (86/609/EU) and Spanish regulations (BOE 67/
8509-12, 1988). Experimental protocols were approved by the Committee for Animal Care
and Handling of the University of Oviedo (Permit number: 9-INV-2004). All surgery was per-
formed under Isoflurane anesthesia (IsoFlo1, Abbott Laboratories, Abbott Park, IL) and ani-
mals were sacrificed using CO2. All efforts were made to minimize animal suffering and to
reduce the number of animals used.
Islet graft
Plasma. Blood was obtained from Wistar rats by venipuncture into 5-mL sodium citrate-
coated sterile tubes (Vacutainer SST™ II Advance; Becton-Dickinson, Plymouth, United King-
dom) and centrifuged at 3000 rpm for 15 min. The plasma was collected and frozen until use.
Pancreatic islets. As previously described [16], Wistar rat pancreas was distended by an
intraductal injection of collagenase type XI (Sigma-Aldrich). The pancreas was then harvested,
incubated in a water bath at 37˚C for 21 min, and the digested tissue washed in Hank’s bal-
anced salt solution (HBSS, Sigma-Aldrich). Islets were separated by Dextran (Sigma-Aldrich)
discontinuous density gradient centrifugation, washed in HBSS, and immediately prepared for
transplant. Islet equivalents (IEQs), purity, and viability were calculated by examining dithi-
zone-stained (Sigma-Aldrich) preparations.
Skin fibroblasts. As previously described [13], a full-thickness skin biopsy specimen (1
cm2) from the right flank of a nu/nu mice was obtained and grinded without previous dermis-
epidermis separation. Then, the homogenate was subjected to enzyme digestion with 2 mg/mL
collagenase (Sigma-Aldrich) at 37˚C for 4 h and the digested tissue suspension was then fil-
tered through a cell strainer (Becton Dickinson) and centrifuged at 1400 rpm for 10 min. The
resultant pellet was suspended in Dulbecco’s modified Eagle’s medium (DMEM, Lonza, Basel,
Switzerland) supplemented with 10% fetal calf serum (Gibco Invitrogen, Paisley, United King-
dom) and antibiotic-antimycotic solution (50 U/ml penicillin + 50 μg/ml streptomycin, Gibco
Invitrogen). Cells were seeded in culture flasks and cultured at 37˚C in a humidified atmo-
sphere of 5% CO2. Fibroblasts were used after 4–5 passages.
Plasma-based scaffold containing islets (PSI). Fresh pancreatic islets (3000 IEQs) were
mixed with 2 mL of plasma alone (PSI) or containing 2 x 105 skin fibroblasts (PSI-F). Then, 5
mg/mL of tranexamid acid (Amchafibrin, Fides-Ecofarm, Barcelona, Spain) was added and
the final volume was adjusted to 4 mL with DMEM + 6.75 mM CaCl2. The mixture was finally
allowed to solidify for 15–20 minutes at 37˚C in a humidified atmosphere of 5% CO2.
Subcutaneous islet transplantation. Transplantation was performed in diabetic mice
7–10 days after STZ injection. The islet graft (PSI or PSI-F) was placed directly over the
abdominal musculature after performing a skin incision. NFBG was monitored periodically
after transplantation on whole blood samples obtained from the tail vein. Normoglycemia was
defined as a NFBG level <200 mg/dL.
Animal groups
The following groups were established:
Diabetic group (n = 8): Non-transplanted diabetic mice (7–10 days after streptozotocin
injection).
Control group (n = 8): Non-transplanted healthy mice.
ISC (n = 8): Diabetic mice subcutaneously transplanted with islets alone.
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PSI (n = 16): Diabetic mice subcutaneously transplanted with PSI.
PSI-F (n = 16): Diabetic mice subcutaneously transplanted with PSI-F.
Intraperitoneal glucose tolerance tests (IPGTTs)
After an overnight fast, the animals received an intraperitoneal glucose bolus (2 g/Kg of body
weight) as a 5% solution in Hanks’ Balanced Salt Solution (Lonza), and blood glucose was
monitored at 0, 15, 30, 60, 90 and 120 min. To evaluate the response to IPGTTs, the “area
under the curve” was calculated for each animal using the trapezoidal rule method [17].
Subcutaneous islet graft gene expression study
Of each experimental group (PSI and PSI-F), two mice were sacrificed at days 1, 3, 7 and 10
after islet transplantation. Each subcutaneous islet graft was divided in halves: one half was
used for total RNA extraction, while the other half was fixed in 4% formaldehyde for histologi-
cal study.
Whole RNA was isolated using TRIzol (Invitrogen) and purified with the RNeasy Mini Kit
(Qiagen). Concentration and quality of samples were determined using a NanoDrop 2000
(Thermoscientific, Wilmington, DE) at A260/A280. Those with the best quality were selected
for hybridization with GeneChip1 Mouse Genome 430 2.0 array (Affymetrix), following the
manufacturer’s instructions. Quality control of microarray data was performed using Affyme-
trix Expression Console. Data are expressed as base-2 exponents. Array data were deposited at
the Gene Expression Omnibus with the accession number GSE84900. Bioinformatic analysis
was performed using the Babelomics platform (http://www.babelomics.org).
Histology
The histological study was performed in subcutaneous grafts of mice sacrificed at days 1, 3, 7,
10 and 90 days after transplantation. After a 24 h fixation in 4% formaldehyde, the specimens
were dehydrated in a graded series of ethanol dilutions and finally embedded in paraffin. Sec-
tions of 4–6 μm thick were obtained using a microtome HM 350 S (Microm, Waldorf, Ger-
many). Some sections were stained with hematoxylin and eosin (H&E). The presence of
functional islets was confirmed by immunohistochemical insulin labelling. Briefly, paraffin
sections were deparaffinized and rehydrated in EZ Prep, and placed in Reaction Buffer. The
primary antibody (Ab) was polyclonal Guinea pig Anti-Insulin (Dako, Glostrup, Denmark).
Sections were incubated at 37˚C with primary Ab (1:60) for 1 h in Ab diluent. Some sections
(those of 1, 3, 7 and 10 days after transplantation) were incubated with the secondary Ab
OmniMap anti-Rb HRP and then, detected with ChromoMap DAB; while other sections
(those of 90 days after transplantation) were incubated with a rabbit anti-guinea pig IgG alka-
line phosphatase conjugated secondary Ab (Abcam, Cambridge, United Kingdom) and visual-
ized using the alkaline phosphatase-chromogen kit (Fast Red™) Ab (Abcam) according to the
manufacturer´s instructions. Contrast staining was performed with hematoxylin. The insulin-
positive area (expressed in μm2) was determined in equivalent areas (6 fields per slide, n = 2
per group at 1, 3, 7 and 10 days or n = 8 per group at 90 days after transplantation). For the
insulin-lectin double staining (90 days after transplantation), insulin was performed as previ-
ously indicated, although donkey anti-guinea pig Cy5 conjugated secondary Ab (Jackson
Laboratories) was used. In addition, Bandeiraea simplicifolia FITC-conjugated lectin (Sigma
Aldrich) was used to detect vessel, and then, mounted with VECTASHIELD Antifade Mount-
ing Medium with DAPI (Vector Laboratories, Burlington, Canada) to stain nuclei and
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examined with a laser scanning confocal microscope TCS-SP8X (Leica, Barcelona, Spain). For
vessel counting, anti-CD31 polyclonal Ab (Abcam) was used. Sections were incubated at 37˚C
with primary Ab (1:50) for 32 min. The secondary Ab used was OmniMap anti-Rb HRP and
detection was carried out with ChromoMap DAB. Contrast staining was performed with
hematoxylin. Vessel number was determined by counting total CD-31 positive vessels
observed on the matrix surrounding islets in equivalent areas (6 fields per slide, n = 2 per
group at 1, 3, 7 and 10 days or n = 8 per group at 90 days after transplantation). On the other
hand, the presence of apoptotic cells was determined by using CF™488A TUNEL Assay Apo-
ptosis Detection Kit (Biotium, Hayward, Canada) according to the manufacturer´s instruc-
tions. Finally, sections were mounted with VECTASHIELD Antifade Mounting Medium with
DAPI (Vector Laboratories) to stain nuclei and examined with a laser scanning confocal
microscope. TUNEL(+) cells per area (in mm2) was determined in equivalent areas (6 fields
per slide, n = 2 per group at 1, 3, 7 and 10 days after transplantation) obtained with the laser
scanning confocal microscope. Beta cell proliferation was determined by using a Guinea pig
anti-insulin Ab (Abcam) and a rabbit anti-Ki67 Ab (Abcam). Sections were incubated with
anti-insulin Ab (1:500) and anti-Ki67 Ab (1:500) for 48h at 4˚C. Next, an Anti-rabbit Ig G
(Alexa Fluor1 647, Abcam) and an anti-Guinea Pig Ig G (Alexa Fluor1 488, Abcam) were
used at 1:1000 and 1:500 respectively. Finally, sections were mounted with VECTASHIELD
Antifade Mounting Medium with DAPI (Vector Laboratories) to stain nuclei and examined
with a laser scanning confocal microscope. Percentage of Ki67(+) Insulin(+) cells per total
Insulin (+) cells were determined in equivalent areas (6 fields per slide, n = 2 per group at 1, 3,
7 and 10 days or n = 8 per group at 90 days after transplantation. All reagents, except where
specified, were from Ventana Medical Systems (Roche group, Tucson, AZ).
Statistical analysis
Results are expressed as mean ± SEM. The significance of differences between two indepen-
dent groups was calculated using the unpaired Student’s t-test. For multiple comparisons,
ANOVA tests were conducted followed by the Scheffe´ post hoc test to determine specific differ-
ences between groups. A p-value<0.05 was considered statistically significant.
Results
Fibroblasts improve long-term survival and function of subcutaneous
islet grafts
Diabetic nude mice were transplanted subcutaneously with islets embedded into a plasma-
based scaffold without cells (PSI) or with fibroblasts (PSI-F). In both groups, hyperglycemia
was reversed in the first days after transplantation (Fig 1A). However, significant differences
were observed: meanwhile PSI-F mice maintained normoglycemia along the 90 days follow-
up, PSI mice showed a progressive deterioration of glycemic control which forced the sacrifice
of some animals due to their critical condition (Fig 1B).
On the other hand, when IPGTTs were performed at the end of the 90-days follow-up, clear
differences were observed among groups (Fig 1C and 1D). While PSI-F mice showed a good
glucose tolerance, similar to that of control mice, PSI mice were not able to reverse hyperglyce-
mia after glucose bolus administration (Fig 1D, 21709±2522 vs. 41004±6341 (mg/dL)min for
PSI-F and PSI, respectively, p<0.01). Nevertheless, PSI mice showed a response significantly
better than that showed by non-transplanted diabetic mice (Fig 1D, 41004±6341 vs. 54896
±3084 (mg/dL)min for PSI and Diabetic, respectively, p<0.05).
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Regarding to the histological study performed on subcutaneous grafts on day 90 after
transplantation, insulin-positive islets and vessels were observed in both PSI and PSI-F mice,
although islets in presence of fibroblasts were bigger and showed a better morphology (Fig
2A). Moderate fibrosis was observed in both groups, with islets embedded by a new collagen-
like matrix, which substituted the initial plasma-based scaffold. However, this matrix was
more organized and vascularized in presence of fibroblasts (Fig 2B, 52±3 vs. 43±2 vessels/field
for PSI-F and PSI, respectively, p<0.05), which correlated with the significantly higher insulin
area observed in this group (Fig 2C, 8125±836 vs. 3335±917 μm2 for PSI-F and PSI, respec-
tively, p<0.001). The increase in insulin area cannot be explained by an induction of beta-cell
proliferation in the presence of fibroblasts since a double Ki67/insulin staining showed no dif-
ferences between both groups (S1 Fig).
Fibroblasts accelerate subcutaneous islet graft vascularization
Taking in mind the differences found between PSI and PSI-F groups 90 days after transplanta-
tion, and the critical influence of the phenomena occurred during the first days after transplan-
tation over long-term results, we focused our study in this early period in order to look for
differences among groups. PSI and PSI-F mice were sacrificed at day 1, 3, 7 and 10 after trans-
plantation, and subcutaneous grafts were retrieved and processed both for histological and
gene expression analysis.
Fig 1. Subcutaneous transplantation of PSI in immunodeficient diabetic mice. (A) Follow up of NFBG in
the following groups (n = 8 per group): (▲, Diabetic) non-transplanted diabetic mice; (♦, ISC) diabetic mice
subcutaneously transplanted with free islets; (■, PSI) diabetic mice subcutaneously transplanted with PSI;
(●, PSI-F) diabetic mice subcutaneously transplanted with PSI containing 2 x 105 fibroblasts. †p<0.001 vs.
PSI and PSI-F; #p<0.05 vs. PSI-F; ‡p<0.01 vs. PSI-F; §p<0.001 vs. PSI-F. (B) Kaplan-Meier mice survival
curve. Groups are the same as detailed in A (n = 8 per group). Mean survival time (MST) is indicated for each
group. †p<0.01 vs. Diabetic; #p<0.001 vs. PSI and PSI-F; ‡p<0.001 vs. Diabetic. (C) Blood glucose responses
to IPGTTs, 90 days after transplantation. Groups are the same as detailed in A, except for (^, Control) non-
transplanted healthy mice (n = 8 per group, except for PSI where n = 5). (D) Area under the curve (AUC) data
obtained from IPGTTs. *p<0.05; **p<0.01.
https://doi.org/10.1371/journal.pone.0180695.g001
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The histological analysis of the grafts (Fig 3A) showed a faster revascularization in presence
of fibroblasts (PSI-F), with a vessel number (Fig 3B) significantly higher at days 1 (3.5±0.3 vs.
13±1.4 vessels/field for PSI and PSI-F, respectively, p<0.001) and 3 (7.75±1.1 vs. 20.5±2.9
vessels/field for PSI and PSI-F, respectively, p<0.01) after transplantation, although these
Fig 2. Histology of subcutaneous islet grafts 90 days after transplantation. (A) Insulin immunostaining and insulin/
lectin immunofluorescence (insulin in red to detect beta cells and lectin in green to detect vessels) performed on both PSI
and PSI-F grafts. (B) Quantification of vessels in the subcutaneous grafts after CD31 immunostaining. (C) Quantification of
the insulin-positive area in the subcutaneous grafts. *p<0.05; ***p<0.001.
https://doi.org/10.1371/journal.pone.0180695.g002
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differences diminished afterwards. However, insulin staining began to be notorious on both
groups at day 7, with no statistically significant differences between them (Fig 3A). As men-
tioned before, no significant differences were observed on beta cell proliferation among groups
(S1 Fig). Since lack of vascularization during this early period after transplantation can induce
cell death, a TUNEL assay was performed. The number of apoptotic cells per field (Fig 3C) was
significantly higher in absence of fibroblasts (PSI) on days 7 (114±12 vs. 60±5 TUNEL(+) cells/
area for PSI and PSI-F, respectively, p<0.01) and 10 (95±16 vs. 53±5 TUNEL(+) cells/area for
PSI and PSI-F, respectively, p<0.05) after transplantation. A fibrotic process was observed in
all samples, being the level of fibrosis higher in presence of fibroblasts (days 1 and 3, mild vs.
Fig 3. Histology of subcutaneous islet grafts along the first 10 days after transplantation. (A)
Histological images of CD31 (to detect vessels) and insulin (to detect beta cells) immunostaining of PSI and
PSI-F grafts at days 1, 3, 7 and 10 after transplantation (Black arrows point to islets and red arrows point to
vessels). (B) Quantification of vessels in the subcutaneous grafts after CD31 immunostaining at days 1, 3, 7
and 10 after transplantation. (C) Quantification of apoptotic cells per area in PSI and PSI-F grafts at days 1, 3,
7 and 10 after transplantation. *p<0.05; **p<0.01; ***p<0.001.
https://doi.org/10.1371/journal.pone.0180695.g003
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moderate for PSI and PSI-F, respectively; days 7 and 10, moderate vs. severe for PSI and PSI-F,
respectively). This fibrotic process seems to be in correlation with the absorption rate of
plasma-based scaffold, which seemed to begin earlier in PSI-F mice, where a new-formed col-
lagen-like matrix was observed at day 10 but not in absence of fibroblasts (Fig 3A).
Fibroblasts exert their activity by inducing a higher expression of pro-
angiogenic and pro-survival factors
In order to look for putative factors that might be important during islet engraftment and its
posterior survival, we performed a gene expression profile of subcutaneous islet grafts. First,
we compared profiles between groups with special attention to those differences shown when
comparing PSI to PSI-F RNA profiles. In this sense, we started our analysis by looking at dif-
ferences of 4-fold difference in gene expression (logFC2) within the day after islet transplanta-
tion and between samples from PSI-F and PSI (Fig 4).
The maximum difference between both groups occurred at day 3 after islet transplantation,
with 177 genes differentially expressed. Day 7 was the following day in terms of number of
genes differentially expressed (78 genes), followed by day 1 (44 genes) and day 10 (39 genes).
When we analyzed these genes using bioinformatic tools available at www.babylomics.com we
could not observe important affected pathways although important genes involved in inflam-
mation, vascularization and islet regeneration and survival could be detected such as Interleu-
kin-6 (IL-6), Interleukin-1beta (IL-1β), Chitinase-3 (Chi-3), Regenerating islet-derived 1
(REG-1) and Regenerating islet-derived 3 gamma (REG-3gamma) (Fig 5A). In all these genes,
an overexpression in presence of fibroblasts could be observed at day 3.
Since all mice were diabetic before islet transplantation, we tried to analyze our array data
with a different approach. In this sense we compared each transplanted group (PSI and PSI-F)
with the Diabetic group. Then, we compared the different expressed genes in search for genes
specifically present in the PSI vs. Diabetic, those specifically present in the PSI-F vs. Diabetic,
and those common to both groups (Fig 5B) (S1–S4 Tables). In this type of analysis we could
also observe that in the first three comparisons (days 1, 3 and 7 after transplantation) more
genes were specific for the PSI-F group (281, 666 and 360 genes, respectively). At these days,
the genes specifically expressed in the PSI group were 135, 118 and 292 genes, respectively. As
opposed, more genes were specific for the PSI group than for the PSI-F group on day 10 (185
vs. 153 genes, for PSI and PSI-F, respectively). Regarding common genes expressed in both
groups the numbers were 768, 665, 667 and 433 genes for days 1, 3, 7 and 10 (Fig 5B). Since
long term survival of islets after transplantation is achieved only in the PSI-F group we used
the specifically expressed genes in this group in search of pathways in which they were
involved using the babylomics platform (Table 1). In this type of analysis we were able to
observe that these genes can be grouped in important pathways that could explain long-
term survival of transplanted islets. Thus, important pathways on vascularization were repre-
sented by genes expressed specifically in PSI-F samples. It is noteworthy how pathways such
as “blood vessel development”, “vasculature development”, “blood vessel morphogenesis” or
“response to hypoxia” showed up on day 3; and pathways related to cell death appeared on day
7 (Table 1).
Discussion
In the present work, we have observed that the use of a plasma-based scaffold alone (PSI)
improved islet engraftment, reversed hyperglycemia and achieved short-term glycemic con-
trol, although long-term control was only achieved when fibroblasts were included in the scaf-
fold before transplantation (PSI-F). The gene expression study performed on the first days
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after transplantation showed how genes related with angiogenesis and β-cell regeneration were
over-expressed in presence of fibroblasts, which correlated with the faster islet graft revascular-
ization, the lower islet lost and the better glycemic control observed in the transplanted ani-
mals of this group.
It is known that plasma-derived scaffold provide to the transplanted islets the initial
mechanical support necessary for graft survival and function [8]. Fibrin is a natural biomate-
rial which has been used previously to promote engraftment mainly at extrahepatic sites [18–
20]. While those fibrin hydrogels are usually obtained by combination of commercially avail-
able fibrin with thrombin, our plasma-based scaffold is obtained by mixing blood plasma with
Fig 4. Genes differentially expressed in PSI group vs. PSI-F group. Heat map represents the relative expression levels of identified genes (logFC2
PSI vs. PSI-F) in each day as determined in a GeneChip Mouse Gene 2.0 Array analysis (being green the higher expression and red the lower). Right
column indicates gene name. Additionally, in each day the heat map for any individual gene represents the variation of its expression during all the
samples taken for our analysis (0, 1, 3, 7 and 10 days). Genes have been arranged from maximum to minimum fold expression differences in any given
day after transplantation.
https://doi.org/10.1371/journal.pone.0180695.g004
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calcium, avoiding the use of fibrinogen or any exogenous pro-coagulant agent. Thus, this
plasma-derived scaffold constitutes a cheaper and safer fibrin-containing hydrogel. In our
work, transplantation of islets combined with the plasma-based scaffold alone (PSI group)
reversed hyperglycemia, although was unable to maintain long-term glycemic control. These
results indicate the necessity of complementing the effect of this scaffold by an additional sup-
porting therapy.
Since islet graft is avascular after isolation, its survival would depend on oxygen and nutri-
ent diffusion from the surrounding microenvironment during the first days after transplanta-
tion. Therefore, a quick reestablishment of a functional vasculature is essential for its
immediate engraftment and thus, for long-term islet survival and function. In spite of the sev-
eral “pros” of the subcutaneous space, its poor vascularization becomes its main “con” as alter-
native to the portal vein infusion. Several factor-based strategies have been attempted in order
to overcome this, although most of them showed limited efficacy [21–27]. Incorporation of
accessory cells with islet-supporting properties could provide several of these factors with pre-
cise control over timing, dose delivery and effect duration [28]. In our model, fibroblasts were
incorporated to the plasma-derived scaffold as graft-supporting cells (PSI-F group). The higher
amount of vessels and the lower number of apoptotic cells found in PSI-F grafts during the
first days after transplantation suggest that fibroblasts promoted early islet revascularization.
Although fibrosis usually constitutes a pathologic and undesired phenomenon in tissue regen-
eration, the fibrotic process observed in this model allowed creating a new vascularized ECM
at the subcutaneous space which is home to the transplanted pancreatic islets. The presence of
fibroblasts in the graft enhanced this fibrotic process and increased vascularization, leading to
Fig 5. Genes expressed on the first ten days after transplantation on subcutaneous islet grafts. (A)
Pattern of expression of Interleukin 6, Interleukin 1 beta, Chitinase 3, Regenerating islet-derived 1 and
Regenerating islet-derived 3 gamma after transplantation. (B) Number of genes specifically expressed in PSI,
PSI-F and commonly expressed in both groups when compared with Diabetic group.
https://doi.org/10.1371/journal.pone.0180695.g005
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Table 1. Pathways represented by specifically expressed genes in PSI-F (www.babelomics.org).
Day 1
Pathway #term adj pvalue
Cytokine-cytokine receptor interaction—Mus musculus (mouse) mmu04060 7.82594E-3
Toll-like receptor signaling pathway—Mus musculus (mouse) mmu04620 4.21797E-3
Cytosolic DNA-sensing pathway—Mus musculus (mouse) mmu04623 2.37377E-2
immune response GO:0006955 1.1332E-5
response to fungus GO:0009620 1.83454E-2
positive regulation of B cell activation GO:0050871 2.26813E-2
tissue morphogenesis GO:0048729 2.97847E-2
cell activation GO:0001775 2.97847E-2
regulation of immune system process GO:0002682 2.97847E-2
mononuclear cell proliferation GO:0032943 2.97847E-2
lymphocyte proliferation GO:0046651 2.97847E-2
cellular response to stimulus GO:0051716 4.81378E-2
tissue development GO:0009888 4.81378E-2
Day 3
Pathway #term adj pvalue
Leukocyte transendothelial migration—Mus musculus (mouse) mmu04670 2.37835E-2
Insulin signaling pathway—Mus musculus (mouse) mmu04910 3.15866E-2
Hematopoietic cell lineage—Mus musculus (mouse) mmu04640 3.15866E-2
enzyme linked receptor protein signaling pathway GO:0007167 4.10724E-8
cell migration GO:0016477 2.20784E-7
cellular component movement GO:0006928 5.94421E-7
organ morphogenesis GO:0009887 1.28216E-5
transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 2.33507E-5
blood vessel development GO:0001568 8.83843E-5
vasculature development GO:0001944 1.01758E-4
regulation of cell communication GO:0010646 1.39045E-4
blood vessel morphogenesis GO:0048514 1.35708E-3
response to hypoxia GO:0001666 2.5248E-3
Day 7
Pathway #term adj pvalue
Asthma—Mus musculus (mouse) mmu05310 3.49504E-4
Systemic lupus erythematosus—Mus musculus (mouse) mmu05322 5.06548E-4
Allograft rejection—Mus musculus (mouse) mmu05330 5.06548E-4
Cell adhesion molecules (CAMs)—Mus musculus (mouse) mmu04514 5.06548E-4
Autoimmune thyroid disease—Mus musculus (mouse) mmu05320 1.52164E-3
Primary immunodeficiency—Mus musculus (mouse) mmu05340 2.95021E-3
Chemokine signaling pathway—Mus musculus (mouse) mmu04062 2.95021E-3
Cytosolic DNA-sensing pathway—Mus musculus (mouse) mmu04623 3.49209E-3
Leukocyte transendothelial migration—Mus musculus (mouse) mmu04670 8.23078E-3
Graft-versus-host disease—Mus musculus (mouse) mmu05332 1.38583E-2
Apoptosis GO:0006915 2.03641E-2
response to oxidative stress GO:0006979 8.94815E-3
cell death GO:0008219 2.03641E-2
cell proliferation GO:0008283 2.9882E-3
programmed cell death GO:0012501 2.29903E-2
regulation of cell proliferation GO:0042127 3.59673E-3
(Continued )
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a higher organized and vascularized ECM that, improved islet engraftment which finally
allowed long-term graft survival and function in this group of mice.
The gene expression analysis performed on the islet grafts during the first days after trans-
plantation revealed over-expression of IL-6, IL1-β and Chi-3 in the group transplanted with
fibroblasts. It is well known that most of these cytokines have a great pro-angiogenic activity
[29]. IL-6 has been previously related with revascularization, function and survival of islets
when co-cultured with MSCs [30], while IL-1β has been identified as the principal effector of
Myc-induced islet angiogenesis [31]. On the other hand, Chi-3 is a lectin that has been also
related with angiogenesis, although mainly associated with cancer progression and metastasis
[32, 33]. Additionally to their role in islet revascularization, both IL-6 and IL-1β seem to col-
laborate on the up-regulation of GLP-1 and insulin production in pancreatic islets [34, 35]. On
the other hand, REG-1 and REG-3gamma were also over-expressed in presence of fibroblasts
during this early post-transplant period. REG family comprises several lectin-like proteins that
have been related with pancreatic β-cell regeneration [36–39]. Furthermore, some studies have
shown that some cytokines, as IL-6 and IL-22, can activate the expression of these REG pro-
teins [40–43]. Taking this in mind, REG proteins could be related with the β-cell proliferation
induced by several cytokines as IL-6 [44]. In our work, overexpression of cytokines and REG
proteins in presence of fibroblasts correlated with the faster islet re-vascularization and the
lower level of apoptosis observed, favouring long-term islet survival and function. Recently, an
interesting in vitro study showed how dermal fibroblasts can promote islet survival by secre-
tion of several cytokines and extracellular matrix proteins [45]. Therefore, our results corrobo-
rate those findings in an “in vivo” model, highlighting the possible use of fibroblasts as graft-
supporting cells, not only in islet transplantation, but also in those other transplants where a
fast graft re-vascularization could be needed. No significant differences were observed in the
expression of pro-angiogenic, hypoxia or apoptosis-related genes. In supplementary figure 2
(S2 Fig) we show how the kinetics and patterns of expression for several genes involved in islet
survival or implicated in islet death as described by Velmurugan et al [46] were very similar
between both groups (PSI-F and PSI). No detection of individual known genes involved in
these pathways could also be attributable to the threshold we established in the gene selection
process, where a minimum 4-fold difference in gene expression between groups was required
to be considered as significant. However, if 1- to 3-fold difference were accepted, an increase
in the expression of some pro-angiogenic genes (VEGF A, VEGF C, Angiopoietin-4, FGF-4,
FGF-12, PDGF-1 and PDGF-B), as well as of the anti-apoptotic gen BCL-2, was observed in
presence of fibroblasts. In fact, it is possible that not only an individual or a small group of
Table 1. (Continued)
defense response GO:0006952 3.75767E-5
response to other organism GO:0051707 8.94815E-3
leukocyte mediated immunity GO:0002443 1.11433E-3
immune response GO:0006955 7.64244E-13
Day 10
Pathway #term adj pvalue
Hematopoietic cell lineage—Mus musculus (mouse) mmu04640 4.53859E-2
Asthma—Mus musculus (mouse) mmu05310 4.89735E-2
antigen processing and presentation of exogenous antigen GO:0019884 3.04511E-3
Significant _kegg_0.05 and significant_go_biological_process_3_9_0.05
https://doi.org/10.1371/journal.pone.0180695.t001
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genes or factors are implicated in engraftment, islet survival, revascularization and even a
proper link to nerve terminals but rather larger groups controlling whole pathways of tissue
morphogenesis are implicated. In this sense, by bioinformatic analysis of our arrays, we have
been able to observe how the presence of fibroblast is able to affect such pathways.
Tissue engineering approaches constitute a promising alternative in order to improve
engraftment in islet transplantation. In addition to the scaffold, the election of the cell type
becomes of the utmost importance. In this work, we have shown how the use of fibroblasts as
graft-supporting cells promoted the expression of genes related with angiogenesis and β-cell
regeneration, decreasing the lost of islets associated to the first days after transplantation and
thus, favoring long-term islet survival and function. Since both plasma and dermal fibroblasts
are of autologous origin and can be easily obtained; this model constitutes a biocompatible,
cheap, safe and reproducible tissue engineering approach available to be used in the clinic.
However, further work is required in order to clarify the specific secretome of fibroblasts in
this model, allowing their possible use in other graft-supporting strategies. Furthermore, com-
bination of this islet transplantation model with new immunoregulatory strategies [47] as the
use of immunomodulatory cells, such as MSCs [14, 48], dendritic cells [49], hematopoietic
stem cells [50] or cord blood-derived stem cells [51], as well as other tolerogenic strategies
[52], would be necessary in order to achieve long-term survival of islet allo- or xenografts in
immunocompetent recipients, avoiding or reducing the use of immunosuppressive drugs and,
perhaps, achieving reversal of diabetes.
Supporting information
S1 Fig. Beta cell proliferation in subcutaneous islet grafts at 3 and 90 days after transplan-
tation. A) Immunohistochemical staining of insulin (green), nuclear proliferating marker ki67
(red) and nucleus (in blue). B) Quantification of proliferating beta cells.
(TIF)
S2 Fig. Kinetics of fold changes in expression of genes involved in islet survival or islet
death.
(TIF)
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S3 Table. Genes specifically or commonly expressed at day 7 after transplantation.
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